Phio Pharmaceuticals Files 8-K
Ticker: PHIO · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Phio Pharma filed an 8-K, no juicy details yet.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on March 30, 2026, to report other events. The filing does not contain specific financial figures or new material agreements, but rather serves as a notification of events.
Why It Matters
This filing indicates that Phio Pharmaceuticals Corp. has had events to report to the SEC, though the specific nature of these events is not detailed in the provided excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting other events without disclosing specific material changes or financial impacts.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Filer
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' as per Item 8.01.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 30, 2026.
What is the CIK number for Phio Pharmaceuticals Corp.?
The CIK number for Phio Pharmaceuticals Corp. is 0001533040.
What is the business address of Phio Pharmaceuticals Corp.?
The business address of Phio Pharmaceuticals Corp. is 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406.
What SIC code is associated with Phio Pharmaceuticals Corp.?
The SIC code associated with Phio Pharmaceuticals Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 9.2 · Accepted 2026-03-30 07:15:34
Key Financial Figures
- $0.0001 — h registered: Common Stock , par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio20260326_8k.htm (8-K) — 23KB
- ex_937626.htm (EX-99) — 10KB
- ex_937626img001.jpg (GRAPHIC) — 2KB
- 0001437749-26-010164.txt ( ) — 171KB
- phio-20260330.xsd (EX-101.SCH) — 3KB
- phio-20260330_def.xml (EX-101.DEF) — 12KB
- phio-20260330_lab.xml (EX-101.LAB) — 15KB
- phio-20260330_pre.xml (EX-101.PRE) — 12KB
- phio20260326_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On March 30, 2026, Phio Pharmaceuticals Corp. (the "Company") issued a press release announcing it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 8.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: March 30, 2026 By: /s/ Robert J. Bitterman Robert J. Bitterman President & Chief Executive Officer 3